Burkhard Tönshoff

TL;DR: Investigation of the pharmacokinetic (PK)/pharmacodynamic relationship of total and free MPA and PK values for the assessment of an individual's MPA PK parameters indicates that therapeutic drug monitoring of MPA has the potential for optimization of MMF efficacy in this patient population by steering patients away from the low values of M PA PK variables that are associated with an increased rejection risk.

TL;DR: The goal of this consensus meeting was to offer information to transplant practitioners on clinically relevant pharmacokinetic characteristics of MPA, to rationalize the basis for currently advised target exposure ranges for MPA in various types of organ transplantation, and to summarize available methods for application of M PA TDM in clinical practice.

TL;DR: Alport syndrome is treatable with angiotensin-converting enzyme inhibition to delay renal failure and therapy improves life expectancy in a time-dependent manner and supports the need for early diagnosis and early nephroprotective therapy in oligosymptomatic patients.

TL;DR: The applied protocol of MMF dose adjustments based on target MPA exposure was not successful, partly because physicians seemed reluctant to implement substantial dose changes.

TL;DR: The children treated with growth hormone had sustained catch-up growth, whereas the control children had progressive growth failure.